Insights
Plain-language articles on clinical trials, conditions, and procedures -- written for patients and partners.
News
Coronary stent procedures at the affiliated cardiovascular ASC in Miami-Dade →
Announcement
Amavita Research Is GCSA-Certified (Feb 2025) →
Patient Resources — Condition-Specific
Heart Failure Clinical Trials — A Patient's Guide →
Patient Resources — Condition-Specific
Hypertension Clinical Trials — A Patient's Guide →
Patient Resources — Condition-Specific
Peripheral Artery Disease Clinical Trials — A Patient's Guide →
Patient Resources — Condition-Specific
Iron Deficiency in Heart Failure Clinical Trials — A Patient's Guide →
Patient Resources — Condition-Specific
Acute Coronary Syndrome Clinical Trials — A Patient's Guide →
Patient Resources — Condition-Specific
Structural Heart Disease Clinical Trials — A Patient's Guide →
Patient Resources
How to Read a Clinical Trial Consent Form — A Patient's Practical Guide →
Patient Resources
What to Expect When You Join a Cardiovascular Clinical Trial →
For Sponsors
Cardiovascular Trial Site Selection Criteria for 2026 →
For Sponsors
US + Latin America Cardiovascular Trial Site Strategy →
Regulatory Strategy
FDA Diversity Action Plans and Cardiovascular Trial Site Selection →
Study Start-Up
November 2, 2026Julio G. Martinez-Clark
For sponsors and CROs: what makes a US site's clinical trial agreement move faster. Reuse an agreement already negotiated, price standard budget lines in a rate card, settle the legal entity and signer at the start, and run IRB work alongside the contract where the sponsor and IRB allow it.
Read moreCTMS
October 29, 2026Amavita Editorial (AI-assisted) AI-assisted
Vendor demos follow the vendor's script. How to sandbox-test a CTMS against your own SOPs, source workflow, integrations and finance reports before you sign.
Read moreprotocol amendment
October 26, 2026Amavita Editorial (AI-assisted) AI-assisted
What 21 CFR 56.108, 56.110, 812.35 and 312.30 require for protocol amendments, where the time goes, and how a Miami cardiovascular site keeps enrollment moving through version changes.
Read moreearly feasibility study
October 26, 2026Amavita Editorial (AI-assisted) AI-assisted
How Amavita Research runs same-day early feasibility cardiovascular device work: 2 operating rooms, 5 recovery beds and cath lab access inside an affiliated, licensed Kendall ASC.
Read moreearly feasibility study
October 26, 2026Amavita Editorial (AI-assisted) AI-assisted
How to design early feasibility protocols for catheter-based devices with same-day observation: telemetry, serial labs, discharge criteria, safety reporting and imaging.
Read morecardiovascular clinical trials
October 26, 2026Amavita Editorial (AI-assisted) AI-assisted
Why a dedicated cardiovascular ASC research setting in Miami can start daytime device protocols faster than a tertiary hospital, and when it is the wrong choice.
Read morecardiovascular clinical trials
October 13, 2026Amavita Editorial (AI-assisted) AI-assisted
Indication map, diagnostics, and same-day Phase 1 work (2 operating rooms and 5 recovery beds in a licensed Kendall cardiovascular ASC) at Amavita Research — without overnight or non-CV claims.
Read morecardiovascular clinical trials
October 13, 2026Amavita Editorial (AI-assisted) AI-assisted
Amavita Research recruits from an active Miami cardiovascular practice panel instead of waiting on passive referrals. What that changes for screening — and what it does not promise.
Read moreSite Operations
October 13, 2026Julio G. Martinez-Clark
Used equipment can build a good site — or quietly disqualify it. Before buying a used ECG or other device for trial work: verify the calibration and service paper trail, confirm the digital export formats central laboratories require, budget IQ/OQ qualification, and run the total cost of ownership.
Read morecardiovascular clinical trials
October 5, 2026Amavita Editorial (AI-assisted) AI-assisted
Amavita Research is a cardiovascular site. How we plan to add immunology and pursue imaging-enabled oncology and neurology scopes as prime site, and what is not true yet.
Read morePhase 1
October 5, 2026Amavita Editorial (AI-assisted) AI-assisted
Amavita Research runs cardiovascular Phase 1 work inside an affiliated Kendall, Miami ASC licensed for 2 operating rooms and 5 recovery beds. Same-day outpatient scope.
Read moreheart failure
August 25, 2026Amavita Editorial (AI-assisted) AI-assisted
Heart failure affects over 6 million adults in the US. Learn about the types, stages, modern treatment options, and how clinical trials are advancing care.
Read moreTAVR
August 22, 2026Amavita Editorial (AI-assisted) AI-assisted
TAVR has evolved beyond the high-risk population. Here is what referring cardiologists need to know about patient selection, procedural advances, and when to refer in 2026.
Read morecardiovascular
August 22, 2026Amavita Editorial (AI-assisted) AI-assisted
Site selection, not protocol design, is the single decision that most often determines whether a cardiovascular trial finishes on time and on budget.
Read moreRegulatory Strategy
May 13, 2026Julio G. Martinez-Clark
How FDA's Diversity Action Plan Final Guidance affects cardiovascular trial site selection: enrollment targets, site demographic profile, sponsor obligations, and how sites like Amavita Research support diverse enrollment in Miami.
Read moreFor Sponsors
May 13, 2026Julio G. Martinez-Clark
When to run a cardiovascular trial across US and Latin America under a single coordinated design: speed-to-FIH, regulatory pathways, patient diversity, cost arbitrage, and operational integration. Amavita Research + bioaccess®.
Read moreFor Sponsors
May 13, 2026Julio G. Martinez-Clark
Comprehensive sponsor decision criteria for evaluating cardiovascular clinical trial sites in 2026: PI continuity, patient flow, contracting speed, cost structure, quality framework, and indication fit.
Read morePatient Resources
May 13, 2026Amavita Research
Plain-language guide for patients considering enrollment in a cardiovascular clinical trial: screening, informed consent, randomization, time commitment, compensation, your rights, and what to expect at every stage.
Read morePatient Resources
May 13, 2026Amavita Research
Plain-language guide to reading a clinical trial informed consent form: what each section means, which sections matter most, common red flags, and questions to ask the trial team before signing.
Read morePatient Resources — Condition-Specific
May 13, 2026Amavita Research
Plain-language guide for patients with structural heart disease (TAVR candidates, mitral valve, congenital adult patients) considering clinical trial participation. Eligibility, what trials are testing, what to expect.
Read morePatient Resources — Condition-Specific
May 13, 2026Amavita Research
Plain-language guide for patients who have had a heart attack or unstable angina considering clinical trial participation: what trials are testing, eligibility, what to expect, and current ACS trials at Amavita Research.
Read morePatient Resources — Condition-Specific
May 13, 2026Amavita Research
Plain-language guide for heart failure patients with iron deficiency considering clinical trial participation: why iron deficiency matters in HF, what IV iron trials are testing, eligibility, what to expect.
Read morePatient Resources — Condition-Specific
May 13, 2026Amavita Research
Plain-language guide for patients with peripheral artery disease considering clinical trial participation: what trials are testing in 2026, eligibility, what to expect, and current PAD trials at Amavita Research.
Read morePatient Resources — Condition-Specific
May 13, 2026Amavita Research
Plain-language guide for patients with high blood pressure considering clinical trial participation: what trials are testing in 2026, eligibility, what to expect, and current hypertension trials at Amavita Research in North Miami Beach, FL.
Read morePatient Resources — Condition-Specific
May 13, 2026Amavita Research
Plain-language guide for patients with heart failure considering clinical trial participation: what trials are testing in 2026, eligibility, what to expect, and current heart failure trials at Amavita Research in North Miami Beach, FL.
Read moreAnnouncement
May 13, 2026Amavita Research
Amavita Research is GCSA-certified (Feb 2025), meeting the Global Quality Standard for Clinical Research Sites established by IAOCR.
Read moreNews
May 13, 2026Amavita Research
On May 13, 2026, Amavita Research performed a coronary stent procedure at the affiliated Kendall ASC (Advanced Cardiovascular of Miami) — a dedicated cardiovascular ambulatory surgery center (ASC) in Miami-Dade. The procedure was led by Dr. Pedro Martinez-Clark.
Read moreheart_failure
April 29, 2026Amavita Editorial (AI-assisted) AI-assisted
Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure where the heart's main pumping chamber squeezes normally but is too stiff to relax and fill with blood properly betwee
Read moreheart_failure
April 29, 2026Amavita Editorial (AI-assisted) AI-assisted
Heart failure with reduced ejection fraction (HFrEF) is a type of heart failure where the heart's main pumping chamber does not squeeze out enough blood with each beat.[1][2][3]
Read morecardiology
April 29, 2026Amavita Editorial (AI-assisted) AI-assisted
Sudden cardiac arrest and heart attack are serious heart emergencies that differ in cause, symptoms, and urgency.
Read morerhythm
April 29, 2026Amavita Editorial (AI-assisted) AI-assisted
A pacemaker is a small, battery-powered device implanted under the skin in the chest that helps your heart beat at a normal, steady rhythm by sending mild electrical impulses when needed.
Read morerhythm
April 29, 2026Amavita Editorial (AI-assisted) AI-assisted
Atrial fibrillation (AFib) is an irregular and often rapid heartbeat that starts in the upper chambers of the heart.
Read moreFor Patients
February 26, 2026Pedro Martinez-Clark, MD, FACC
From the first phone call through the final follow-up visit, here is a step-by-step look at what participating in a cardiovascular clinical trial actually involves.
Read moreClinical Research Basics
February 19, 2026Pedro Martinez-Clark, MD, FACC
Drug clinical trials are organized into phases. Each one answers different safety and effectiveness questions. Here is what each phase is for, in plain language.
Read moreClinical Research Basics
February 12, 2026Pedro Martinez-Clark, MD, FACC
First-in-human (FIH) trials are the first time a new therapy is studied in people. Here is how protocols, oversight, and site experience combine to keep participants safe.
Read moreConditions & Procedures
February 5, 2026Pedro Martinez-Clark, MD, FACC
Atherectomy is an endovascular technique that removes or modifies arterial plaque, often used in calcified peripheral artery disease. Here is how it works.
Read moreConditions & Procedures
January 29, 2026Pedro Martinez-Clark, MD, FACC
PAD affects millions of adults in the U.S. Learn the warning signs, how it is diagnosed, and the modern range of treatment options — including ongoing clinical research.
Read moreConditions & Procedures
January 22, 2026Pedro Martinez-Clark, MD, FACC
TAVR is a minimally invasive procedure that replaces a diseased aortic valve through a catheter — without open-heart surgery. Here is how it works and who it helps.
Read moreFor Patients
January 15, 2026Pedro Martinez-Clark, MD, FACC
Eligibility for a cardiovascular clinical trial depends on the study's protocol — but the basic principles are the same across trials. Here is how qualification works.
Read moreClinical Research Basics
January 8, 2026Pedro Martinez-Clark, MD, FACC
A clear, plain-language explanation of cardiovascular clinical trials — what they study, how they protect participants, and the role they play in advancing heart and vascular care.
Read moreAsistan IA, se pa yon moun. Tanpri pa mete enfòmasyon sou sante w.